Apr 29, 2026, 8:05 PMglobenewswire.comVCNX
Vaccinex Reports 2025 Annual Financial Results
Financial reportsLegal proceedings
ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer's, Huntington's disease, and cancer today released financial results for the year ended December 31, 2025. The financial statements have been posted on the company website.
